Skye Bioscience, Inc. Current Income Tax Expense (Benefit)
Skye Bioscience, Inc. (SKYE) reported Current Income Tax Expense (Benefit) of $5.40 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-10
- Skye Bioscience, Inc. current income tax expense (benefit) for fiscal 2025 was $5.40K, a 46.38% decline from fiscal 2024.
- Skye Bioscience, Inc. current income tax expense (benefit) for fiscal 2024 was $10.07K, a 179.75% increase from fiscal 2023.
- Skye Bioscience, Inc. current income tax expense (benefit) for fiscal 2023 was $3.60K, a 46.60% decline from fiscal 2022.
- Skye Bioscience, Inc. current income tax expense (benefit) for fiscal 2022 was $6.74K, a 221.00% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $5.40K 10-K · filed 2026-03-10 |
| 2024-12-31 | $10.07K 10-K · filed 2026-03-10 |
| 2023-12-31 | $3.60K 10-K · filed 2025-03-20 |
| 2022-12-31 | $6.74K 10-K · filed 2024-03-22 |
| 2021-12-31 | $2.10K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |